1. Home
  2. SCYX vs XBP Comparison

SCYX vs XBP Comparison

Compare SCYX & XBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$2.97

Market Cap

37.9M

Sector

Health Care

ML Signal

HOLD

Logo XBP Europe Holdings Inc.

XBP

XBP Europe Holdings Inc.

SELL

Current Price

$3.00

Market Cap

39.9M

ML Signal

SELL

Company Overview

Basic Information
Metric
SCYX
XBP
Founded
1999
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Business Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
37.9M
39.9M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
SCYX
XBP
Price
$2.97
$3.00
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
★ $32.67
N/A
AVG Volume (30 Days)
★ 59.4K
3.3K
Earning Date
11-05-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
61.36
★ 183.67
EPS
★ N/A
N/A
Revenue
$257,000.00
★ $872,690,000.00
Revenue This Year
N/A
$2.47
Revenue Next Year
$977.86
$10.86
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.66
$0.41
52 Week High
$6.09
$8.55

Technical Indicators

Market Signals
Indicator
SCYX
XBP
Relative Strength Index (RSI) 26.17 42.23
Support Level $0.66 $2.54
Resistance Level $4.15 $3.00
Average True Range (ATR) 0.25 0.16
MACD -0.04 0.01
Stochastic Oscillator 4.17 29.71

Price Performance

Historical Comparison
SCYX
XBP

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About XBP XBP Europe Holdings Inc.

XBP Global Holdings Inc is a multinational technology and services company that drives intelligent workflows for organizations. Through its proprietary platforms, agentic AI-driven automation, and domain expertise across industries and the public and private sectors, the firm enables its clients to entrust their digital transformations and workflows. The segments of the company are Applied Workflow Automation and Technology. The Applied Workflow Automation segment generates maximum revenue and provides services powered by intelligent, AI-enabled workflows that generate outcomes for client's systems, while the Technology segment focuses on the sale of recurring and perpetual software licenses, software maintenance and professional services, as well as hardware solutions and maintenance.

Share on Social Networks: